Mavacamten: Initial Insights From the Risk Evaluation and Mitigation Strategy Program

Matthew W Martinez; Dewey Seto; Michael Cheung; Michele Coiro; Niki Patel; Arnaud Bastien; Jeffrey Lockman; Sonia Afsari; Milind Y Desai

doi:10.1016/j.jacadv.2024.101430

Mavacamten: Initial Insights From the Risk Evaluation and Mitigation Strategy Program

JACC Adv. 2024 Dec 9;4(1):101430. doi: 10.1016/j.jacadv.2024.101430. eCollection 2025 Jan.

Authors

Matthew W Martinez¹, Dewey Seto², Michael Cheung², Michele Coiro², Niki Patel², Arnaud Bastien², Jeffrey Lockman², Sonia Afsari², Milind Y Desai³

Affiliations

¹ Hypertrophic Cardiomyopathy Center, Morristown Medical Center, Atlantic Health System, Morristown, New Jersey, USA.
² Bristol Myers Squibb, Princeton, New Jersey, USA.
³ Hypertrophic Cardiomyopathy Center, Heart Vascular Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.

No abstract available

Keywords: hypertrophic cardiomyopathy; left ventricular ejection fraction; mavacamten; obstructive HCM; risk evaluation and mitigation strategy; septal reduction therapy.